CoChat

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

Ferrari, C. I., Abs, R., Bevan, J. S., Brabant, G., Ciccarelli, E., Motta, T., Mucci, M., Muratori, M., Musatti, L., Verbessem, G., Scanlon, M. F. · 1997 · Clinical Endocrinology
Cited by 154

The DOI matches its Crossref record.

Abstract

OBJECTIVE Cabergoline is now established as an effective and well‐tolerated treatment for prolactinoma. However, there are relatively few published data on the treatment of macro‐, as opposed to micro‐, prolactinoma. We have therefore reviewed the efficacy and safety of cabergoline in the treatment of patients with prolactin‐secreting macroadenomas treated on a compassionate basis. STUDY DESIGN AND PATIENTS Eighty‐five patients with prolactin‐secreting macroadenomas were treated with cabergoline 0.25 to 10.5 mg per week (median 1 mg) given in one to seven doses. Treatment durations ranged between 3 months and 8 years. Sixty‐five patients (32 intolerant, 16 resistant) had been treated previously with other dopamine agonists. Pretreatment prolactin levels ranged between 80 and 8300 μg/l and tumour maximum diameters were between 11 and 42 mm. MEASUREMENTS Serum prolactin, visual fields if initially abnormal, occurrence of menses or return of libido and potency, blood chemistry and adverse events were assessed at 1 month and then at 3‐month intervals during treatment. Pituitary computed tomography or magnetic resonance imaging was usually repeated at 3 months and 1 year, then yearly, in most patients (n=62). RESULTS Normalization of prolactin levels was achieved in 52 patients (61.2%) and a prolactin decrease of at least 75% of pretreatment values occurred in 24 others (28.2%). Of the 20 de novo patients, 17 had prolactin normalized and the remainder had at least 75% reduction. Disappearance of tumour image was found in eight of 62 evaluable patients (12.9%) and reduction of the largest diameter by at least 25% in another 33 (53.2%), with an overall success rate of 66.1%; among the 17 evaluable de novo patients the success rate was 82.3%. Fifteen of 21 patients who failed to show tumour shrinkage had previously demonstrated resistance/intolerance to other prolactin‐lowering treatments. Of the 12 patients with visual field defects at baseline, six normalized and two showed an improvement. Menses resumed during cabergoline treatment in 79.5% of premenopausal women. Restoration of potency was reported by seven of eight evaluable men. Adverse events were recorded in 24.7% of cases, four of whom (4.7%) discontinued treatment. CONCLUSIONS Although the present data were not obtained in a formal study we conclude that cabergoline is an effective and well‐tolerated treatment for macroprolactinoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.1997.1300952.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 154

Metadata

Authors
Ferrari, C. I., Abs, R., Bevan, J. S., Brabant, G., Ciccarelli, E., Motta, T., Mucci, M., Muratori, M., Musatti, L., Verbessem, G., & Scanlon, M. F.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1997-04
Volume
46
Issue
4
Pages
409-413
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2049638429
Cited by
154
References
0
FWCI
5.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. https://app.cochat.ai/papers/10.1046/j.1365-2265.1997.1300952.x
The paper
Ferrari, C. I., Abs, R., Bevan, J. S., Brabant, G., Ciccarelli, E., Motta, T., Mucci, M., Muratori, M., Musatti, L., Verbessem, G., & Scanlon, M. F. (1997). Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1997.1300952.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.